Treatment of tumor-bearing mice with the PERK small-molecule inhibitors GSK2656157 or GSK2606414 has also resulted in significant anti-tumor effects [49, 91], but it remains unknown whether these compounds could additionally relieve immunosuppression in the tumor microenvironment by controlling activation in myeloid cells, without inducing systemic toxicity. Here, EIF2AK3 is linked to neoplasm.